Giant Cell Arteritis In Adults — Patent Landscape
1
Approved drugs
85
Active US patents
42/100
Avg vulnerability
$5.3B
Annual revenue covered
Originators in Giant Cell Arteritis In Adults
Cliff calendar — next 15 years
4
31
4
33
71
36
6
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Rinvoq
upadacitinib
|
AbbVie Inc. | 85 | 42 | $5.3B | 2031-01-15 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8962629 | Rinvoq | method of use | 81 | 2031-01-15 |
| 8962629 | Rinvoq | method of use | 76 | 2031-01-15 |
| 8962629 | Rinvoq | method of use | 76 | 2031-01-15 |
| 11993606 | Rinvoq | method of use | 75 | 2036-10-17 |
| 12365689 | Rinvoq | method of use | 75 | 2036-10-17 |
| 11976077 | Rinvoq | method of use | 75 | 2036-10-17 |
| 11993605 | Rinvoq | method of use | 75 | 2036-10-17 |
| 12365689 | Rinvoq | method of use | 75 | 2036-10-17 |
| 11512092 | Rinvoq | method of use | 70 | 2036-10-17 |
| 11524964 | Rinvoq | method of use | 70 | 2036-10-17 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11186584 | Rinvoq | composition of matter | 4 | 2036-10-17 |
| 9951080 | Rinvoq | composition of matter | 4 | 2036-10-17 |
| 10981923 | Rinvoq | composition of matter | 4 | 2036-10-17 |
| RE47221 | Rinvoq | composition of matter | 4 | 2033-08-16 |
| 11773105 | Rinvoq | composition of matter | 12 | 2036-10-17 |
| 9951080 | Rinvoq | composition of matter | 12 | 2036-10-17 |
| 11773105 | Rinvoq | composition of matter | 12 | 2036-10-17 |
| 11718627 | Rinvoq | composition of matter | 12 | 2036-10-17 |
| 11718627 | Rinvoq | composition of matter | 12 | 2036-10-17 |
| 11680069 | Rinvoq | composition of matter | 12 | 2036-10-17 |
Related
- Giant Cell Arteritis In Adults — full disease profile
- AI Patent Landscape Report — type "giant cell arteritis in adults" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner